Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis

View ORCID ProfileShinichi Namba, Takahiro Konuma, View ORCID ProfileKuan-Han Wu, View ORCID ProfileWei Zhou, Global Biobank Meta-analysis Initiative, View ORCID ProfileYukinori Okada
doi: https://doi.org/10.1101/2021.12.03.21267280
Shinichi Namba
1Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shinichi Namba
Takahiro Konuma
1Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
2Central Pharmaceutical Research Institute, JAPAN TOBACCO INC., Takatsuki 569-1125, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuan-Han Wu
3Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kuan-Han Wu
Wei Zhou
4Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
5Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wei Zhou
Yukinori Okada
1Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
6Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan
7Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita 565-0871, Japan
8Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita 565-0871, Japan
9Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita 565-0871, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yukinori Okada
  • For correspondence: yokada@sg.med.osaka-u.ac.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Genomics-driven drug discovery is indispensable for accelerating the development of novel therapeutic targets. However, the drug discovery framework based on evidence from genome-wide association studies (GWAS) has not been established, especially for cross-population GWAS meta-analysis. Here, we introduce a practical guideline for genomics-driven drug discovery for cross-population meta-analysis, as lessons from the Global Biobank Meta-analysis Initiative (GBMI). Our drug discovery framework encompassed three methodologies and was applied to the 13 common diseases targeted by GBMI (Nmean = 1,329,242). First, we evaluated the overlap enrichment between disease risk genes and the drug-target genes of the disease-relevant medication categories. An omnibus approach integrating the four gene prioritization tools yielded twice the enrichment in the disease-relevant medication categories compared with any single tool, and identified drugs with approved indications for asthma, gout, and venous thromboembolism. Second, we performed an endophenotype Mendelian randomization analysis using protein quantitative trait loci as instrumental variables. After the application of quality controls, including a colocalization analysis, significant causal relationships were estimated for 18 protein–disease pairs, including MAP2K inhibitors for heart failure. Third, we conducted an in silico screening for negative correlations between genetically determined disease case–control gene expression profiles and compound-regulated ones. Significant negative correlations were observed for 31 compound–disease pairs, including a histone deacetylase inhibitor for asthma. Integration of the three methodologies provided a comprehensive catalog of candidate drugs for repositioning, nominating promising drug candidates targeting the genes involved in the coagulation process for venous thromboembolism. Our study highlighted key factors for successful genomics-driven drug discovery using cross-population meta-analysis.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by AMED, JSPS, and JST.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data used in the present study are publicly available

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted December 05, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis
Shinichi Namba, Takahiro Konuma, Kuan-Han Wu, Wei Zhou, Global Biobank Meta-analysis Initiative, Yukinori Okada
medRxiv 2021.12.03.21267280; doi: https://doi.org/10.1101/2021.12.03.21267280
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis
Shinichi Namba, Takahiro Konuma, Kuan-Han Wu, Wei Zhou, Global Biobank Meta-analysis Initiative, Yukinori Okada
medRxiv 2021.12.03.21267280; doi: https://doi.org/10.1101/2021.12.03.21267280

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (171)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8797)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1867)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (493)
  • Hematology (207)
  • HIV/AIDS (396)
  • Infectious Diseases (except HIV/AIDS) (10579)
  • Intensive Care and Critical Care Medicine (565)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1763)
  • Nursing (104)
  • Nutrition (267)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (966)
  • Ophthalmology (284)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1846)
  • Public and Global Health (3992)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (536)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)